ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2024, Vol. 16 ›› Issue (5): 425-430.doi: 10.3969/j.issn.1674-3865.2024.05.014

• 临床研究 • 上一篇    下一篇

中医药联合重组人生长激素治疗儿童特发性矮小症的Meta分析

吴依师, 张秀英, 李兆洋, 王雪峰   

  1. 110000 沈阳,辽宁中医药大学第一临床学院2024级中医儿科学专业研究生(吴依师,李兆洋);110032 沈阳,辽宁中医药大学附属医院儿科(张秀英,王雪峰)

  • 收稿日期:2024-10-10 修回日期:2024-10-12 出版日期:2024-10-25 上线日期:2024-10-25
  • 通讯作者: 张秀英,E-mail:1370264413@qq.com
  • 基金资助:
    王雪峰全国名老中医药专家传承工作室建设项目(国中医药人教发[2022]75号);王雪峰辽宁省中医大师传承工作室建设项目(2022-1)

Meta-analysis of traditional Chinese medicine combined with recombinant human growth hormone in the treatment of children with idiopathic short stature

WU Yishi1,ZHANG Xiuying2,LI Zhaoyang1,WANG Xuefeng2   

  1. 1The First Clinical College of Liaoning University of Traditional Chinese Medicine,Shenyang 110000,China;2Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,China
  • Received:2024-10-10 Revised:2024-10-12 Published:2024-10-25 Online:2024-10-25
  • Contact: ZHANG Xiuying,E-mail:1370264413@qq.com

摘要: 目的:系统评价中医药联合重组人生长激素与单纯应用重组人生长激素在儿童特发性矮小症治疗中的临床疗效,为临床治疗提供循证参考。方法:检索中国知网、维普、万方、中国生物医学文献数据库、Pubmed从建库到2024年9月30日符合纳入排除标准的文献,应用软件RevMan 5.4进行统计分析。结果:共纳入19篇随机对照临床试验,病例1 756例,其中观察组873例,对照组883例。Meta分析结果显示,应用中医药联合重组人生长激素治疗特发性矮小症,在提高总有效率,患儿身高、体质量、生长速率,胰岛素样生长因子1及胰岛素样生长因子结合蛋白3水平均明显优于单纯应用重组人生长激素,且不良反应发生率低于单纯应用重组人生长激素。结论:中医药联合重组人生长激素治疗儿童特发性矮小症疗效显著。

关键词: 特发性矮小症, 中西医结合, 随机对照试验, 分析, 儿童

Abstract: Objective:To systematically assess the clinical efficacy of traditional Chinese medicine in conjunction with recombinant human growth hormone, as well as that of recombinant human growth hormone alone, in the treatment of children with idiopathic short stature, thereby providing an evidence-based reference for clinical treatment. Methods:CNKI, VIP, Wanfang, CBM, and Pubmed were searched for literature that met the inclusion and exclusion criteria from the establishment of the database to September 30, 2024. RevMan 5.4 software was used for statistical analysis.Results:A total of 19 randomized controlled clinical trials with 1 756 patients were included, including 873 cases in the observation group and 883 cases in the control group. The results of Meta-analysis showed that the application of traditional Chinese medicine combined with recombinant human growth hormone in the treatment of idiopathic short stature was significantly better than the simple application of recombinant human growth hormone in improving the total effective rate, height, weight, growth rate, insulin-like growth factor 1 and insulin-like growth factor binding protein 3 levels, and the incidence of adverse reactions was lower than the simple application of recombinant human growth hormone.Conclusion:The integration of traditional Chinese medicine with recombinant human growth hormone demonstrates significant efficacy in the treatment of children with idiopathic short stature.

Key words: Idiopathic short stature, Integrated traditional Chinese and western medicine, Randomized controlled trial, Meta-analysis, Child